Immunotherapy with genetically modified immune cells increases survival of patients with aggressive B lymphoma who do not respond to chemotherapy
Two studies published in The New England Journal of Medicine, with the participation of IDIBELL and the ICO, present the results of two phase 3 clinical trials comparing treatment with CART lymphocytes versus conventional treatment with chemotherapy and bone marrow transplantation.